247 related articles for article (PubMed ID: 16236891)
21. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation.
Shah RM; Sexauer W; Ostrum BJ; Fiel SB; Friedman AC
AJR Am J Roentgenol; 1997 Aug; 169(2):375-80. PubMed ID: 9242738
[TBL] [Abstract][Full Text] [Related]
22. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
Fitzgerald DA; Hilton J; Jepson B; Smith L
Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
[TBL] [Abstract][Full Text] [Related]
23. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
Bryson HM; Sorkin EM
Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.
Ranasinha C; Assoufi B; Shak S; Christiansen D; Fuchs H; Empey D; Geddes D; Hodson M
Lancet; 1993 Jul; 342(8865):199-202. PubMed ID: 8100928
[TBL] [Abstract][Full Text] [Related]
26. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
Johnson CA; Butler SM; Konstan MW; Breen TJ; Morgan WJ
J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143
[TBL] [Abstract][Full Text] [Related]
27. [Multicenter study of rhDNase in cystic fibrosis with severe pulmonary involvement].
Hodson M
Arch Pediatr; 1995 Jul; 2(7):679-81. PubMed ID: 7663660
[TBL] [Abstract][Full Text] [Related]
28. Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease.
Robinson TE; Goris ML; Moss RB; Tian L; Kan P; Yilma M; McCoy KS; Newman B; de Jong PA; Long FR; Brody AS; Behrje R; Yates DP; Cornfield DN
Pediatr Pulmonol; 2020 Apr; 55(4):929-938. PubMed ID: 31962004
[TBL] [Abstract][Full Text] [Related]
29. Dornase alpha and exhaled NO in cystic fibrosis.
Grasemann H; Lax H; Treseler JW; Colin AA
Pediatr Pulmonol; 2004 Nov; 38(5):379-85. PubMed ID: 15390350
[TBL] [Abstract][Full Text] [Related]
30. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
[TBL] [Abstract][Full Text] [Related]
31. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.
Wilmott RW; Amin RS; Colin AA; DeVault A; Dozor AJ; Eigen H; Johnson C; Lester LA; McCoy K; McKean LP; Moss R; Nash ML; Jue CP; Regelmann W; Stokes DC; Fuchs HJ
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1914-7. PubMed ID: 8665055
[TBL] [Abstract][Full Text] [Related]
32. An automated approach to quantitative air trapping measurements in mild cystic fibrosis.
Goris ML; Zhu HJ; Blankenberg F; Chan F; Robinson TE
Chest; 2003 May; 123(5):1655-63. PubMed ID: 12740287
[TBL] [Abstract][Full Text] [Related]
33. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
34. Retrospective review of the effects of rhDNase in children with cystic fibrosis.
Davies J; Trindade MT; Wallis C; Rosenthal M; Crawford O; Bush A
Pediatr Pulmonol; 1997 Apr; 23(4):243-8. PubMed ID: 9141109
[TBL] [Abstract][Full Text] [Related]
35. Improved air trapping evaluation in chest computed tomography in children with cystic fibrosis using real-time spirometric monitoring and biofeedback.
Kongstad T; Buchvald FF; Green K; Lindblad A; Robinson TE; Nielsen KG
J Cyst Fibros; 2013 Dec; 12(6):559-66. PubMed ID: 23810566
[TBL] [Abstract][Full Text] [Related]
36. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis.
Ademhan Tural D; Yalçın E; Emiralioglu N; Ozsezen B; Sunman B; Nayir Buyuksahin H; Guzelkas I; Dogru D; Ozcelik U; Kiper N
Pediatr Pulmonol; 2022 Jan; 57(1):142-151. PubMed ID: 34687284
[TBL] [Abstract][Full Text] [Related]
37. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
[TBL] [Abstract][Full Text] [Related]
38. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
39. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation.
Bakker EM; Volpi S; Salonini E; van der Wiel-Kooij EC; Sintnicolaas CJ; Hop WC; Assael BM; Merkus PJ; Tiddens HA
Eur Respir J; 2011 Dec; 38(6):1328-35. PubMed ID: 21737560
[TBL] [Abstract][Full Text] [Related]
40. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis.
Amin R; Subbarao P; Lou W; Jabar A; Balkovec S; Jensen R; Kerrigan S; Gustafsson P; Ratjen F
Eur Respir J; 2011 Apr; 37(4):806-12. PubMed ID: 20693248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
